<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>targeted drug delivery systems &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/targeted-drug-delivery-systems/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Mon, 27 Oct 2025 16:36:57 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>targeted drug delivery systems &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Vitamin-Engineered Nanoplatforms: Transforming Precision Oncology with Advanced Immunotherapy, Targeted Drug Delivery, and Theranostic Innovations</title>
		<link>https://bioengineer.org/vitamin-engineered-nanoplatforms-transforming-precision-oncology-with-advanced-immunotherapy-targeted-drug-delivery-and-theranostic-innovations/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 27 Oct 2025 16:36:25 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[precision oncology immunotherapy]]></category>
		<category><![CDATA[targeted drug delivery systems]]></category>
		<category><![CDATA[theranostic cancer innovations]]></category>
		<category><![CDATA[Tumor microenvironment modulation]]></category>
		<category><![CDATA[vitamin-engineered nanoplatforms]]></category>
		<guid isPermaLink="false">https://bioengineer.org/vitamin-engineered-nanoplatforms-transforming-precision-oncology-with-advanced-immunotherapy-targeted-drug-delivery-and-theranostic-innovations/</guid>

					<description><![CDATA[In the relentless quest to conquer cancer, precision oncology has emerged as a beacon of hope, aiming to tailor treatments to the unique molecular and cellular landscapes of individual tumors. Yet, this ambition grapples with formidable challenges—tumor heterogeneity, therapeutic resistance, and the elusive tumor immune microenvironment (TME), which often conspires against effective treatment. A pioneering [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">287241</post-id>	</item>
		<item>
		<title>Nanomedicine: A New Frontier in Targeting Metastasis</title>
		<link>https://bioengineer.org/nanomedicine-a-new-frontier-in-targeting-metastasis/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Fri, 12 Sep 2025 13:16:42 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[metastatic cascade intervention]]></category>
		<category><![CDATA[nanomedicine in metastatic cancer]]></category>
		<category><![CDATA[nanoparticle-enhanced immunotherapy]]></category>
		<category><![CDATA[RNA-based cancer therapeutics]]></category>
		<category><![CDATA[targeted drug delivery systems]]></category>
		<guid isPermaLink="false">https://bioengineer.org/nanomedicine-a-new-frontier-in-targeting-metastasis/</guid>

					<description><![CDATA[Metastatic cancer continues to be one of the most formidable challenges in oncology, largely due to its complex and multifaceted nature. Traditional treatments frequently fall short, unable to effectively target the intricacies associated with cancer spread. However, the advent of nanomedicine offers promising avenues for intervention against metastatic disease. Nanomedicine formulations, which harness the unique [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">268902</post-id>	</item>
		<item>
		<title>Southampton Team Pioneers Next-Generation Cancer Treatments</title>
		<link>https://bioengineer.org/southampton-team-pioneers-next-generation-cancer-treatments/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 10 Sep 2025 15:43:14 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[chronic inflammation therapies]]></category>
		<category><![CDATA[Horizon Europe MSCA funding]]></category>
		<category><![CDATA[next-generation cancer treatments]]></category>
		<category><![CDATA[oligonucleotide therapy development]]></category>
		<category><![CDATA[targeted drug delivery systems]]></category>
		<guid isPermaLink="false">https://bioengineer.org/southampton-team-pioneers-next-generation-cancer-treatments/</guid>

					<description><![CDATA[A pioneering international consortium led by the University of Southampton has secured a substantial £3.8 million grant from the prestigious Horizon Europe Marie Skłodowska-Curie Actions (MSCA) programme to revolutionize treatments for cancer and chronic inflammation. This ambitious initiative merges the expertise of ten academic research groups, four innovative companies, a hospital, and a non-profit organisation, [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">268375</post-id>	</item>
	</channel>
</rss>
